Literature DB >> 8946471

A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.

T Yokoi1, Y Kosaka, M Chida, K Chiba, H Nakamura, T Ishizaki, M Kinoshita, K Sato, F J Gonzalez, T Kamataki.   

Abstract

The CYP2D6 gene of a Japanese sparteine poor metabolizer (PM, proband) showing a urinary sparteine metabolic ratio of 31.6 was analysed, and a heterozygous CYP2D6(D), a deletional type, was found by restriction fragment length polymorphism analysis with Xba I enzyme. The PM did not have any other previously described mutations in the CYP2D6 gene causing the loss of catalytic activity of the CYP2D6 enzyme. Thus, a possible new allele(s) responsible for the PM phenotype was analysed. The results indicated that the PM possessed a new 9-base insertion in exon 9, designated CYP2D6(J9). The CYP2D6(J9) and CYP2D6(D) alleles were clarified to be inherited from the mother [2D6(W)/2D6(J9)] and the father [2D6(W)/2D6(D)], respectively. The 9-base insertion caused a large increase in the apparent K(m) value for bufuralol 1'-hydroxylation as examined by expression of the enzyme protein in yeast. Four of 300 Japanese carried a heterozygous CYP2D6(J9) allele (0.7%, 4/600 chromosomes) as determined by a polymerase chain reaction analysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946471     DOI: 10.1097/00008571-199610000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  6 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population.

Authors:  Akihiro Ishiguro; Takahiro Kubota; Hiroshi Sasaki; Yasuhiko Yamada; Tatsuji Iga
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 3.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.

Authors:  S McElroy; C Sachse; J Brockmoller; J Richmond; M Lira; D Friedman; I Roots; B M Silber; P M Milos
Journal:  AAPS PharmSci       Date:  2000

5.  Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Authors:  A Gaedigk; A Bhathena; L Ndjountché; R E Pearce; S M Abdel-Rahman; S W Alander; L DiAnne Bradford; P K Rogan; J Steven Leeder
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.